These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36372869)

  • 21. Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels <70 mg/dL.
    Fujihara Y; Nakamura T; Horikoshi T; Obata JE; Fujioka D; Watanabe Y; Watanabe K; Kugiyama K
    Circ J; 2019 May; 83(6):1302-1308. PubMed ID: 30996151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
    Oyama K; Giugliano RP; Blazing MA; Park JG; Tershakovec AM; Sabatine MS; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2021 Oct; 78(15):1499-1507. PubMed ID: 34620406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
    Bangalore S; Breazna A; DeMicco DA; Wun CC; Messerli FH;
    J Am Coll Cardiol; 2015 Apr; 65(15):1539-48. PubMed ID: 25881936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
    Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
    Schwartz GG; Gabriel Steg P; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Jukema JW; Kim YU; Li QH; Manvelian G; Pordy R; Sourdille T; White HD; Szarek M;
    Circulation; 2021 Mar; 143(11):1109-1122. PubMed ID: 33438437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial.
    Giugliano RP; Wiviott SD; Blazing MA; De Ferrari GM; Park JG; Murphy SA; White JA; Tershakovec AM; Cannon CP; Braunwald E
    JAMA Cardiol; 2017 May; 2(5):547-555. PubMed ID: 28291866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
    Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
    Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
    Zhao SP; Yu BL; Peng DQ; Huo Y
    Atherosclerosis; 2014 Apr; 233(2):707-712. PubMed ID: 24603217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
    J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relation of renal function to mid-term prognosis of stable angina patients with high- or low-dose pitavastatin treatment: REAL-CAD substudy.
    Abe M; Ozaki Y; Takahashi H; Ishii M; Masunaga N; Ismail TF; Iimuro S; Fujita R; Iwata H; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Fukumoto Y; Hokimoto S; Miyauchi K; Ogawa H; Daida H; Shimokawa H; Saito Y; Matsuzaki M; Akao M; Kimura T; Nagai R
    Am Heart J; 2021 Oct; 240():89-100. PubMed ID: 34174217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy.
    Ndrepepa G; Braun S; Tada T; Guerra E; Schunkert H; Laugwitz KL; Kastrati A
    Cardiovasc Revasc Med; 2014 Apr; 15(3):131-6. PubMed ID: 24630704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol.
    Lee KH; Jeong MH; Kim HM; Ahn Y; Kim JH; Chae SC; Kim YJ; Hur SH; Seong IW; Hong TJ; Choi DH; Cho MC; Kim CJ; Seung KB; Chung WS; Jang YS; Rha SW; Bae JH; Cho JG; Park SJ;
    J Am Coll Cardiol; 2011 Oct; 58(16):1664-71. PubMed ID: 21982310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol.
    Lee SY; Oh SJ; Kim EJ; Oum CY; Park SH; Oh J; Kim JS; Kim BK; Park S; Chang HJ; Hong GR; Ko YG; Kang SM; Choi D; Ha JW; Hong MK; Jang Y; Chung N; Lee SH
    PLoS One; 2016; 11(11):e0166246. PubMed ID: 27824924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effects of two low-density lipoprotein cholesterol goals for secondary prevention after acute myocardial infarction in real-world practice: ≥ 50% reduction from baseline versus <70 mg/dL.
    Cho KH; Jeong MH; Park KW; Kim HS; Lee SR; Chae JK; Hong YJ; Kim JH; Ahn Y; Cho JG; Park JC;
    Int J Cardiol; 2015; 187():478-85. PubMed ID: 25846658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment.
    Leibowitz M; Karpati T; Cohen-Stavi CJ; Feldman BS; Hoshen M; Bitterman H; Suissa S; Balicer RD
    JAMA Intern Med; 2016 Aug; 176(8):1105-13. PubMed ID: 27322095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
    Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N
    J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease.
    Ishii J; Kashiwabara K; Ozaki Y; Takahashi H; Kitagawa F; Nishimura H; Ishii H; Iimuro S; Kawai H; Muramatsu T; Naruse H; Iwata H; Tanizawa-Motoyama S; Ito H; Watanabe E; Matsuyama Y; Fukumoto Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Hokimoto S; Miyauchi K; Ohtsu H; Izawa H; Ogawa H; Daida H; Shimokawa H; Saito Y; Kimura T; Matsuzaki M; Nagai R
    J Atheroscler Thromb; 2022 Oct; 29(10):1458-1474. PubMed ID: 34880156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.
    Deedwania P; Murphy SA; Scheen A; Badariene J; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
    JAMA Cardiol; 2021 Feb; 6(2):139-147. PubMed ID: 32785614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
    Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.